enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Blinatumomab - Wikipedia

    en.wikipedia.org/wiki/Blinatumomab

    Blinatumomab linking a T cell to a malignant B cell. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor.

  3. Bi-specific T-cell engager - Wikipedia

    en.wikipedia.org/wiki/Bi-specific_T-cell_engager

    Blinatumomab links T cells with CD19 receptors found on the surface of B cells. The Food and Drug Administration (US) and the European Medicines Agency approved this therapy for adults with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.

  4. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    Blinatumomab: Treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in people aged one month of age and older [2] Budesonide: For twelve weeks of treatment in people aged eleven years of age and older with eosinophilic esophagitis [2]

  5. Inotuzumab ozogamicin - Wikipedia

    en.wikipedia.org/wiki/Inotuzumab_ozogamicin

    Inotuzumab ozogamicin is used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [4] [5]In March 2024, the FDA approved inotuzumab ozogamicin for the treatment of children aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

  6. Teclistamab - Wikipedia

    en.wikipedia.org/wiki/Teclistamab

    Teclistamab, sold under the brand name Tecvayli, is a human bispecific monoclonal antibody used for the treatment of relapsed and refractory multiple myeloma. [8] It is a bispecific antibody that targets the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (), which is expressed on the surface of malignant multiple myeloma B-lineage cells.

  7. Chemotherapy-induced nausea and vomiting - Wikipedia

    en.wikipedia.org/wiki/Chemotherapy-induced...

    Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.

  8. Zanidatamab - Wikipedia

    en.wikipedia.org/wiki/Zanidatamab

    Zanidatamab, sold under the brand name Ziihera, is a humanized monoclonal antibody used for the treatment of HER2-positive biliary tract cancer. [1] [2] It is an IgG-like bispecific HER2-directed antibody directed against two non-overlapping domains of HER2.

  9. Dot blot - Wikipedia

    en.wikipedia.org/wiki/Dot_blot

    A general dot blot protocol involves spotting 1–2 microliters of a samples onto a nitrocellulose or PVDF membrane and letting it air dry. Samples can be in the form of tissue culture supernatants, blood serum, cell extracts, or other preparations. [4]